Clinical Trial

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
Protocol Amendment History 1 change
notable Trial sites expanded: 31 -> 43 locations 2026-07-19
Trial Details
NCT Number NCT07412704
Lead Sponsor Bristol-Myers Squibb
Conditions Arthritis, Rheumatoid
Enrollment 84 participants
Start Date 2026-09-15
Primary Completion 2029-10-30 (estimated)
Study Completion 2030-09-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-17